J&J H1 sales up despite ‘headwinds’ impacting beauty and skin health
Personal care major Johnson & Johnson (J&J) has reported a rise in first half (H1) sales for 2022 despite a dip in pre-adjusted profits and consumer health sales hit by COVID-19, input costs and supply issues.